Defunct Company
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
774
NCT01273922
Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 31, 2011
Completion: Dec 31, 2011
NCT01447407
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
Start: Sep 30, 2011
Completion: Dec 31, 2012
NCT01926028
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase: Phase 1/2
Start: Jul 31, 2013
Completion: May 31, 2016
NCT03455309
Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization
Phase: Phase 2
Start: Jan 30, 2018
Completion: Oct 15, 2019